ArticleClinical and diagnostic laboratory immunology1998
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis.
Article in Clinical and diagnostic laboratory immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis.NPJ vaccines · 2023Article
- The Role of Complement System and the Immune Response to Tuberculosis Infection.Medicina (Kaunas, Lithuania) · 2021Review
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- Innate Immune Pattern Recognition Receptors of Mycobacterium tuberculosis: Nature and Consequences for Pathogenesis of Tuberculosis.Advances in experimental medicine and biology · 2021Article
- Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.Frontiers in immunology · 2019Review
- Complement Dependent and Independent Interaction Between Bovine Conglutinin andFrontiers in immunology · 2018Article
- Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis.Emerging microbes & infections · 2017Article
- Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.The Journal of infectious diseases · 2016Article
- B cells and antibodies in the defense against Mycobacterium tuberculosis infection.Immunological reviews · 2015Review
- Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Cold Spring Harbor perspectives in medicine · 2014Review
- Antibody-mediated immunity against tuberculosis: implications for vaccine development.Cell host & microbe · 2013Review
- Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells.PloS one · 2012Article
- Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens.Clinical and vaccine immunology : CVI · 2006Article
- Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.Infection and immunity · 2005Article
- A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis.Clinical and experimental immunology · 2004Article
- Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.Infection and immunity · 2004Article
- Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci.Infection and immunity · 2002Article
- Effect of mycobacterial phospholipids on interaction of Mycobacterium tuberculosis with macrophages.Infection and immunity · 2001Article
- Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.Infection and immunity · 2000Article
- MPB70 and MPB83 as indicators of protein localization in mycobacterial cells.Infection and immunity · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined alternative and classical complement activation induced by whole bacilli of Mycobacterium bovis BCG and Mycobacterium tuberculosis products. After exposure to BCG, there were higher levels of the terminal complement complex in sera from Indian tuberculosis patients than in sera from healthy controls. The addition of BCG with or without EGTA to these sera indicated that approximately 70 to 85% of the total levels of the terminal complement complex was formed by classical activation. Sera from Indian tuberculosis patients contained more antibody to lipoarabinomannan (LAM) than sera from healthy Indians. Levels of anti-LAM immunoglobulin G2 (IgG2), but not anti-LAM IgM, correlated positively with classical activation induced by BCG in the sera. By flow cytometry, deposition of C3 and terminal complement complex on bacilli incubated with normal human serum was demonstrated. The anticomplement staining was significantly reduced in the presence of EGTA and EDTA. Flow cytometry also revealed the binding of complement to BCG incubated with rabbit anti-LAM and then with factor B-depleted serum. This indicates that classical activation plays a major role in complement activation induced by mycobacteria and that anti-LAM IgG on the bacilli can mediate this response. Classical complement activation may be important for the extent of phagocytosis of M. tuberculosis by mononuclear phagocytes, which may influence the course after infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.